Anavex Life Sciences (AVXL) Total Liabilities (2011 - 2025)

Anavex Life Sciences (AVXL) has 15 years of Total Liabilities data on file, last reported at $6.4 million in Q4 2025.

• For the quarter ending Q4 2025, Total Liabilities fell 51.47% year-over-year to $6.4 million; the trailing twelve-month figure through Dec 2025 stood at $6.4 million (down 51.47% YoY), and the FY2025 full-year result was $8.9 million, down 41.54% from the prior year.
• Total Liabilities slipped to $6.4 million in Q4 2025, from $8.9 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $160.3 million in Q1 2022 to a low of $6.4 million in Q4 2025.
• A 5-year average of $37.4 million and a median of $12.5 million in 2023 frame the typical range for Total Liabilities.
• Across the five-year window, Total Liabilities surged 1627.68% in 2022 and tumbled 93.1% in 2023, its largest moves.
• Tracing AVXL's Total Liabilities over 5 years: stood at $156.9 million in 2021, then slumped by 91.56% to $13.2 million in 2022, then declined by 5.68% to $12.5 million in 2023, then increased by 5.07% to $13.1 million in 2024, then tumbled by 51.47% to $6.4 million in 2025.
• Business Quant data shows AVXL's Total Liabilities at $6.4 million in Q4 2025, $8.9 million in Q3 2025, and $11.5 million in Q2 2025.